Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Enanta reported Q2 revenue of $17.2 million, up from $14.9 million year-over-year, driven by higher royalties from AbbVie’s MAVYRET sales. The company significantly narrowed its net loss to $13.1 million, or $0.45 per share, compared to a loss of $22.6 million in the prior year, benefiting from lower R&D and G&A expenses. Pipeline progress included the initiation of Phase 1 dosing for EDP-978, a KIT inhibitor for chronic urticaria, with topline data expected in Q4 2026. The company remains on track to file an IND for its STAT6 inhibitor EPS-3903 in the second half of 2026 and is conducting enabling activities for a pivotal study of Zelicapavir in high-risk RSV patients.
Key figures
- Revenue
- $17.2 million
- Net loss
- $13.1 million
- Ga expenses
- $9.6 million
- Rd expenses
- $19.4 million
- Cash and securities
- $227 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.